Filtered By:
Education: Study
Therapy: Statin Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 6106 results found since Jan 2013.
A cardiovascular polypill for secondary stroke prevention in a tertiary centre in Ghana (SMAART): a phase 2 randomised clinical trial
Lancet Glob Health. 2023 Oct;11(10):e1619-e1628. doi: 10.1016/S2214-109X(23)00347-9.ABSTRACTBACKGROUND: A cardiovascular polypill containing generic drugs might facilitate sustained implementation of and adherence to evidence-based treatments, especially in resource-limited settings. However, the impact of a cardiovascular polypill in mitigating atherosclerotic risk among stroke survivors has not been assessed. We aimed to compare a polypill regimen with usual care on carotid intima-media thickness (CIMT) regression after ischaemic stroke.METHODS: In SMAART, a phase 2 parallel, open-label, assessor-masked, randomised clini...
Source: Atherosclerosis - September 21, 2023 Category: Cardiology Authors: Fred Stephen Sarfo Jenifer Voeks Sheila Adamu Benedict Apaw Agyei Manolo Agbenorku Nyantakyi Adu-Darko Mercy Adomah Oteng Vida Obese Rexford Adu Gyamfi Nathaniel Adusei Mensah Raelle Tagge Michael Ampofo Samuel Amoabeng Kontoh Samuel Blay Nguah Bruce Ovbi Source Type: research
Statins and portal hypertension: a systematic review and meta-analysis of randomized controlled trials
CONCLUSION: Treatment with statins did not decrease significantly portal hypertension.PMID:37723637 | DOI:10.2174/0929867331666230918114451
Source: Current Medicinal Chemistry - September 19, 2023 Category: Chemistry Authors: Tannaz Jamialahmadi Željko Reiner Maryam Matbou Riahi Seyed Ahmad Emami Zahra Tayarani-Najaran Sepideh Salehabadi Prashant Kesharwani Khalid Al-Rasadi Amirhossein Sahebkar Source Type: research
Evaluating the prevalence of lipid assessments in children in Alberta, Canada
CMAJ Open. 2023 Sep 19;11(5):E820-E825. doi: 10.9778/cmajo.20220163. Print 2023 Sep-Oct.ABSTRACTBACKGROUND: Familial hypercholesterolemia is a common, inherited, life-threatening and treatable condition that is characterized by marked elevations of low-density lipoprotein cholesterol (LDL-C), resulting in a high risk of cardiovascular disease, but treatment starting in childhood dramatically reduces this risk. We sought to evaluate the prevalence of pediatric lipid assessments among children in Alberta.METHODS: We reviewed laboratory and administrative data from Alberta Health between Apr. 1, 2012, and Dec. 31, 2021. We ev...
Source: cmaj - September 19, 2023 Category: General Medicine Authors: Susan Christian Ross Ridsdale Mu Lin Michael Khoury Source Type: research
Statins and portal hypertension: a systematic review and meta-analysis of randomized controlled trials
CONCLUSION: Treatment with statins did not decrease significantly portal hypertension.PMID:37723637 | DOI:10.2174/0929867331666230918114451
Source: Current Medicinal Chemistry - September 19, 2023 Category: Chemistry Authors: Tannaz Jamialahmadi Željko Reiner Maryam Matbou Riahi Seyed Ahmad Emami Zahra Tayarani-Najaran Sepideh Salehabadi Prashant Kesharwani Khalid Al-Rasadi Amirhossein Sahebkar Source Type: research
Pravastatin for lowering lipids
CONCLUSIONS: Pravastatin lowers blood total cholesterol, LDL cholesterol and triglyceride in a dose-dependent linear fashion. This review did not provide a good estimate of the incidence of harms associated with pravastatin because of the lack of reporting of adverse effects in 48.4% of the randomized placebo-controlled trials.PMID:37721222 | DOI:10.1002/14651858.CD013673.pub2
Source: Cochrane Database of Systematic Reviews - September 18, 2023 Category: General Medicine Authors: Stephen P Adams Nima Alaeiilkhchi Sara Tasnim James M Wright Source Type: research
Diseases of the Coronary Microcirculation: Diagnosis and Treatment
CONCLUSION: Approximately 25% of patients with CMD have symptoms that do not respond to intensive treatment with the currently available modalities. New treatments, including interventional therapies, are being studied. Their long-term benefit remains to be assessed and compared to that of the existing methods.PMID:37721132 | DOI:10.3238/arztebl.m2023.0205
Source: Deutsches Arzteblatt International - September 18, 2023 Category: General Medicine Authors: Helen Ullrich-Daub Steffen Daub Maximilian Olschewski Thomas M ünzel Tommaso Gori Source Type: research
Nurse Practitioner Care Compared to Primary Care or Nephrologist Care in Early CKD
CONCLUSIONS: Nurse practitioner care for patients with CKD was associated with better guideline-concordant care than primary care alone or nephrologist care, with clinical outcomes that were better than or equivalent to primary care alone, and similar to those with care by nephrologists.PMID:37721865 | DOI:10.2215/CJN.0000000000000305
Source: Clinical Journal of the American Society of Nephrology : CJASN - September 18, 2023 Category: Urology & Nephrology Authors: Matthew T James Tayler D Scory Ellen Novak Braden J Manns Brenda R Hemmelgarn Aminu K Bello Pietro Ravani Bhavneet Kahlon Jennifer M MacRae Paul E Ronksley Source Type: research
Atherosclerosis as a Risk Factor for IBD: A Population-Based Case-Control Study
CONCLUSIONS: A history of an atherosclerotic-related condition is associated with increased odds of developing IBD, particularly among older adults. Future studies should investigate whether drugs targeting atherosclerotic-related inflammation may prevent IBD in higher-risk individuals.PMID:37721310 | DOI:10.14309/ajg.0000000000002502
Source: Atherosclerosis - September 18, 2023 Category: Cardiology Authors: Adam S Faye Jordan Axelrad Jiangwei Sun Jonas Halfvarson Jonas S öderling Ola Ol én Jonas F Ludvigsson Source Type: research
Molecular Complex of HSIM-loaded Polymeric Nanoparticles: Potential Carriers in Osteoporosis
CONCLUSION: Bone-targeting nanoparticles incorporating functionalized simvastatin can target bone. Thus, in order to distribute simvastatin subcutaneously for the treatment of osteoporosis, the developed nanoparticles may act as a promising approach.PMID:37718521 | DOI:10.2174/1389450124666230915092910
Source: Current Drug Targets - September 18, 2023 Category: Drugs & Pharmacology Authors: Malkiet Kaur Manju Nagpal Amarjot Kaur Grewal Samrat Chauhan Chander Parkash Dora Thakur Gurjeet Singh Source Type: research
Pravastatin for lowering lipids
CONCLUSIONS: Pravastatin lowers blood total cholesterol, LDL cholesterol and triglyceride in a dose-dependent linear fashion. This review did not provide a good estimate of the incidence of harms associated with pravastatin because of the lack of reporting of adverse effects in 48.4% of the randomized placebo-controlled trials.PMID:37721222 | PMC:PMC10506175 | DOI:10.1002/14651858.CD013673.pub2
Source: Cochrane Database of Systematic Reviews - September 18, 2023 Category: General Medicine Authors: Stephen P Adams Nima Alaeiilkhchi Sara Tasnim James M Wright Source Type: research
Nurse Practitioner Care Compared to Primary Care or Nephrologist Care in Early CKD
CONCLUSIONS: Nurse practitioner care for patients with CKD was associated with better guideline-concordant care than primary care alone or nephrologist care, with clinical outcomes that were better than or equivalent to primary care alone, and similar to those with care by nephrologists.PMID:37721865 | DOI:10.2215/CJN.0000000000000305
Source: Clinical Journal of the American Society of Nephrology : CJASN - September 18, 2023 Category: Urology & Nephrology Authors: Matthew T James Tayler D Scory Ellen Novak Braden J Manns Brenda R Hemmelgarn Aminu K Bello Pietro Ravani Bhavneet Kahlon Jennifer M MacRae Paul E Ronksley Source Type: research
Atherosclerosis as a Risk Factor for IBD: A Population-Based Case-Control Study
CONCLUSIONS: A history of an atherosclerotic-related condition is associated with increased odds of developing IBD, particularly among older adults. Future studies should investigate whether drugs targeting atherosclerotic-related inflammation may prevent IBD in higher-risk individuals.PMID:37721310 | DOI:10.14309/ajg.0000000000002502
Source: Atherosclerosis - September 18, 2023 Category: Cardiology Authors: Adam S Faye Jordan Axelrad Jiangwei Sun Jonas Halfvarson Jonas S öderling Ola Ol én Jonas F Ludvigsson Source Type: research
Molecular Complex of HSIM-loaded Polymeric Nanoparticles: Potential Carriers in Osteoporosis
CONCLUSION: Bone-targeting nanoparticles incorporating functionalized simvastatin can target bone. Thus, in order to distribute simvastatin subcutaneously for the treatment of osteoporosis, the developed nanoparticles may act as a promising approach.PMID:37718521 | DOI:10.2174/1389450124666230915092910
Source: Current Drug Targets - September 18, 2023 Category: Drugs & Pharmacology Authors: Malkiet Kaur Manju Nagpal Amarjot Kaur Grewal Samrat Chauhan Chander Parkash Dora Thakur Gurjeet Singh Source Type: research
